An interventional study of Physical rehabilitation. in Lung Transplant and Rehabilitation, sponsored by The Alfred. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-09.
Sponsored by The Alfred · Not applicable, Interventional, and Treatment
This randomized, feasibility trial (n=40) will compare the effects of an intensive, twice daily inpatient physical rehabilitation program against standard care (once daily) following double lung transplantation.
This trial will involve the participation of patients post lung transplantation, in the initial post-operative period. Recruitment will take place as soon as the patient is medically safe and willing to commence physical rehabilitation within the intensive care unit. Current, standard care for inpatient physical rehabilitation post lung transplant involves a once daily session of physiotherapy for the duration of the patient's initial inpatient stay, and consists of early mobility, aerobic exercise, upper and lower limb strengthening and flexibility or core muscle re-training.
This trial aims to assess the feasibility and safety of twice daily physical rehabilitation sessions during the post-operative period following lung transplantation. The content of the additional physical rehabilitation session will not differ from, but will complement current standard care, and will be delivered by a trained research assistant or physiotherapist. To the investigator's knowledge, there is no current evidence to support the dosage and intensity of inpatient physical rehabilitation following lung transplantation, and it is unsatisfactory to use evidence from other patient groups to guide practice in this area.
To assess the feasibility of an intensive, inpatient physical rehabilitation program post lung transplantation, the investigators will collect the following data: Number of patients eligible for study inclusion; number of patients consented; number of additional, intensive physical rehabilitation sessions completed; reasons for non-completion of sessions; and attrition, or patient withdrawal rate. In order to assess the safety of the program, the investigators will also assess for evidence of early, acute rejection of the transplanted lungs based on the routine collection of tissue samples, and adverse events. Adverse events will be defined as any event likely caused by acute physical rehabilitation, including musculoskeletal injury, patient fall and surgical wound breakdown.
These assessments will be complemented by a number of physical and psychological outcome measures and patient statistics, including tests of physical capacity, participation and strength, quality of life, requirements for additional physical rehabilitation and/or hospital readmissions within 10 weeks of study commencement, discharge destination and patient length of stay data. Assessments will be completed within 3 days of first time to mobilize, after three weeks and finally after 10 weeks post-transplant.
The investigators hypothesise that an intensive, physical rehabilitation program will be safe and feasible to implement in the post-operative phase post lung transplantation, and that participants in the intensive rehabilitation group will be more active at 10 days, and at 10 weeks than those receiving standard, post lung transplant physical rehabilitation.
The Alfred is the lead sponsor of 45 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
Other: Physical rehabilitation.
Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
Other: Physical rehabilitation.
Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
Ability to deliver intensive inpatient physical rehabilitation (feasibility).
Quantified by number of patients eligible for inclusion; number of patients consented; number of additional, intensive physical rehabilitation sessions completed during the initial, inpatient stay post operatively; reasons for non-completion of sessions; and attrition. This will be aggregated into an overall percentage of successful delivery of intervention.
Time frame: Patient length of stay is typically two to three weeks following lung transplant surgery.
Incidence of treatment and non-treatment related adverse events (safety).
Evidence of early, acute rejection on bronchoscopic biopsy and adverse events. Adverse events will be defined as any adverse outcome during the study period, including but not limited to events that could be related to acute physical rehabilitation such as musculoskeletal injury, patient fall and surgical wound dehiscence or breakdown.
Time frame: Patient length of stay is typically two to three weeks following lung transplant surgery.
Six-minute walk test.
Distance walked in six minutes.
Time frame: Pre-transplant results if available. Repeated at 3 and 10 weeks.
Physical activity monitoring (Dynaport®).
Physical activity levels.
Time frame: 7 days (5 days of data) at post-operative day 10 and at 10 weeks.
Pain visual analogue scale (VAS).
0-10 pain score.
Time frame: Once daily on physical activity monitoring days, from day 10 - 16 post-transplant, repeated for seven days at 10 weeks post-transplant.
EuroQol EQ-5D-5L.
Health-related quality of life questionnaire.
Time frame: Baseline (within 3 days from first time to mobilise), 3 weeks and 10 weeks post-transplant.
Sit to stand test - 60 second.
Amount of sit-stands completed over 60 seconds.
Time frame: Baseline (within 3 days from first time to mobilise), inpatient discharge (2-3 weeks), one month and three months.
Grip strength.
Hand-held dynamometer.
Time frame: Baseline (within 3 days from first time to mobilise), 3 weeks and 10 weeks post-transplant.
Modified Iowa Level of Assistance Scale (MILOA).
A valid, reliable and responsive scale of physical capacity in the post-operative patient.
Time frame: Baseline (within 3 days from first time to mobilise), 3 weeks and 10 weeks post-transplant.
Length of stay.
Length of intensive care and total inpatient stay.
Time frame: Until inpatient discharge, estimated between two to three weeks.
Readmission rates
Readmission rates to the acute setting for the duration of study follow-up.
Time frame: Inpatient discharge (2-3 weeks) to 10 weeks.
Discharge destination.
Requirement for formal inpatient physical rehabilitation vs home.
Time frame: Inpatient (acute) discharge, estimated between two to three weeks.
Rejection rates.
Evidence of any form of chronic lung allograft dysfunction / antibody mediated rejection.
Time frame: Baseline to 10 weeks.
Spirometry
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and forced expiratory ratio (FER)).
Time frame: 10 weeks.
Adherence to outpatient pulmonary rehabilitation.
Post-transplant outpatient physical rehabilitation uptake - sessions completed.
Time frame: Inpatient discharge (2-3 weeks) to 10 weeks.
Plan to share: No — IPD will not be shared outside of this trial.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Alfred